Anis Toumeh, MD
@anistoumeh
Medical Oncologist. Focus on #BreastCancer. Lifelong learner š Travel āļø Hike š„¾ Cook š„ Workout šļøāāļø Video games š® Tweets are my own opinions.
ID: 1658061795633004546
15-05-2023 10:49:43
467 Tweet
294 Followers
245 Following
Atypical ductal or lobular hyperplasia, LCIS, flat epithelial atypia, and future risk of developing breast cancer: meta-analysis 5- and 10-Year Risk Estimatesš LCISā”ļø9.3% - 11.8% ADHā”ļø6.6% - 13.9% ALHā”ļø9.7% - 15.4% LNā”ļø8.6% - 17.0% FEAā”ļø3.8% - 7.2% thebreastonline.com/article/S0960-ā¦
Patients with residual disease (RD) after NACT are at high risk of recurrence. But are all RD equal? In this JAMA Oncology piece we dissect the anatomical, biological & immunological heterogeneity of RD, suggesting a framework to improve treatment tailoring. jamanetwork.com/journals/jamaoā¦
Couldn't agree more, my takeaways were: š aggressive disease (younger women and G3) not surprisingly had higher pCR to chemo š pCR leads to improved OS (5%) š® ADCs for RD will hopefully significantly improve upon capecitabine #ESMO24 #ESMOAmbassadors Manon de Graaf
All good points by Vinay Prasad MD MPH breaking down the LEAP-012. There has been a trend of getting "too excited, too early" in the recent years. We all want to improve our patients' outcomes, but we want to wait for the right endpoints. #ESMO2024
Day 3 #ESMO24 highlights: 1. #KN522: Update TNBC 2. #NIAGARA: resectable MIBC Tom Powles Petros Grivas 3. #CONTACT02: Update mCRPC Neeraj Agarwal, MD, FASCO 4. #NICHE2: dMMR Colon Ca Myriam Chalabi 1/5 #OncTwitter ESMO - Eur. Oncology OncoAlert #bcsm #gism #MedTwitter